Nutlin-3

目录号：S1061

Molecular Weight(MW): 581.5

Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1515.15	现货
5mg	RMB 900.36	现货
10mg	RMB 1407.13	现货
25mg	RMB 3026.07	现货
100mg	RMB 7939.67	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献11篇：

Hepatology, 2015, 62(5):1497-510

PubMed: 26173433

Int J Cancer, 2014, 10.1002/ijc.29194

PubMed: 25196217

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263

Cell Death Dis, 2012, 3:e294

PubMed: 22476102

Cell Death Dis, 2011, 2:e243

PubMed: 22170099

J Cell Physiol, 2018, 233(9):7424-7434

PubMed: 29663367

Int J Oncol, 2014, 44(3):761-8

PubMed: 24366007

Transl Oncol, 2013, 6(6):685-96

PubMed: 24466371

Med Oncol, 2016, 33(10):113

PubMed: 27586146

PLoS One, 2014, 9(9):e108758

PubMed: 25268132

Universidade de Lisboa, 2014, Matias

PubMed:

客户使用该产品的5个实验数据：

Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.
J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.
d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述

Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。

靶点

Mdm2 ^[5]
(Cell-free assay)

180 nM

体外研究

Nutlin-3有效抑制MDM2-p53相互作用，IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞，如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性，IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时，显著诱导caspase依赖的细胞凋亡，凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力，IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力，而3 μM Nutlin-3 处理SJSA-1细胞后，细胞则无活力。^[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化，在特定DNA结合序列没有区别，且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比，使p53靶点基因转活，说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。^[2] 虽然与MDM2相比，Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1)，能抑制MDMX–p53相互作用，且诱导 p53通路，IC50为0.7 μM。^[3] 30 μM Nutlin-3作用于无野生型p53的细胞，也扰乱内源性p73-HDM2 相互作用，且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制，和诱导凋亡。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[1xsDPxE1?	NWH4Z2hWPDkEoHi=		NFv2UYJjdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN?	NXnm[ZhROjZ\|NUC1OlU>
NP69	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\zSo46UUN3ME2zNU43QcLzMj61OEDPxE1?	NUjQRZppOjZ{NUK1O\|U>
NP460	M2PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\jOYNKSzVyPUKyMlg2yrFzLkG4JO69VQ>?	M{P6WFI3OjV{NUe1
C666-1	NXnKdYVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELHcZlKSzVyPUG5Mlk2yrF6LkmzJO69VQ>?	M2\QZ\|I3OjV{NUe1
C666-1	M1zYTmNmdGxiVnnhZoltcXS7IFHzd4F6	NGjPOJAyOCEEtV2=	MYi0PEBp	MYXEUXNQ	NWm2UZFIe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu	NITDOXkzPjJ3MkW3OS=>
C666-1	M13WfGZ2dmO2aX;uJGF{e2G7	NWnjTItKOTBiwsXN	M1O1U\|I1KGh?	NEXZRnZFVVOR	MnnZZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z	MnjUNlYzPTJ3N{W=
C666-1	NYfl[XZbSXCxcITvd4l{KEG\|c3H5	NEfVW4IyOCEEtV2=	MWq0PE84OiCq	MWfEUXNQ	MnL5d4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	NETnd28zPjJ3MkW3OS=>
A549	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkniNlQhcA>?		MlzaTWM2OD1zNz62PEDDuSB2LkWyJO69VQ>?	NXH3WnhuOjZzMkWyN\|A>
A549-NTC	M4W2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHK3cJgzPCCq		MlfVTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>?	NWL6e5FEOjZzMkWyN\|A>
A549-920	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzBe5czPCCq		M4G0TmlEPTB;M{OuPFUhyrFiND64OEDPxE1?	NGDVOZczPjF{NUKzNC=>
CRL-5908	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1L1b\|I1KGh?		NFzJXm1KSzVyPUO4MlcyKMLzIEKuOFMh\|ryP	NX3UXGVyOjZzMkWyN\|A>
L6	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnk[VJHOTEEoN88UeKh	MoXtNlQwPDhxN{KgbC=>	NITIbJhFVVOR	M37kTIlvcGmkaYTzJINmdGy\|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>?	Mlr5NlU5PzF5OUS=
C2C12	NWDTNGtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;qNVDDqM7:TdMg	MWCyOE81QC95MjDo	M4fSSWROW09?	M4jC[olvcGmkaYTzJINmdGy\|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>?	M{m5RlI2QDdzN{m0
MCF-7	NFrvWVlHfW6ldHnvckBCe3OjeR?=	NVq1[pU{OTEEoN88US=>		MWfEUXNQ	M3W5SIlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>?	MoH3NlU4ODJ5MEO=
DU4475	M1jG[mZ2dmO2aX;uJGF{e2G7	M4jMT\|UwOTBxMkCg{txO	NHHkZ4MzPMLiaB?=		NYq0SVlv\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>?	NEH6TVMzPTV2N{G3OC=>
SMMC-7721	NGrBfolHfW6ldHnvckBCe3OjeR?=	MYqxNEDPxE1?	NX\lWopmPDhiaB?=	NVPPUpRHTE2VTx?=	MYnjZZV{\XNiRF7BJGRUSiCmYX3h[4U>	NIHR[FgzPTV2NEO2NS=>
SMMC-7721	M3rQTWZ2dmO2aX;uJGF{e2G7	MUSxNEDPxE1?	MVW0PEBp	MUDEUXNQ	NWTLfnIycW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>?	NG\vZZkzPTV2NEO2NS=>
SMMC-7721	MlziSpVv[3Srb36gRZN{[Xl?	MYGxNEDPxE1?	MkLoOFghcA>?	M1q1bGROW09?	NG\0bJNqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3dCpGlHVkJzwrDtVm5C	MkTMNlU2PDR\|NkG=
SMMC-7721	MljCSpVv[3Srb36gRZN{[Xl?	M3zpSlExKM7:TR?=	M4HWRlM3KGh?	NFTPZ2JFVVOR	MoDhZ4F2e2W\|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY>	NHjyVY8zPTV2NEO2NS=>
MCF-7	NVLFT3hPTnWwY4Tpc44hSXO\|YYm=	M3O2OFExyqEQvF2=	NUHnbow4OC1{NDDo		NGLTXWJqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG=	M3TRWVI2PDh{M{ez
OVCAR10	M4\EWmZ2dmO2aX;uJGF{e2G7	NE\QRlkyOMLizszN	Mo[2NlFpyqB?	NU\IV5RiTE2VTx?=	Mk\2bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=>	NGXCPWkzPTR{NkW0PC=>
NCI-H23	MlK3SpVv[3Srb36gRZN{[Xl?	Mn;INVDDqM7:TR?=	MkS1NlFpyqB?	NILqUWVFVVOR	M4nlTolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM>	MoL2NlU1OjZ3NEi=
A2780	NGHFbXhHfW6ldHnvckBCe3OjeR?=	NWDsUY1GOTEEoN88US=>	Mn3ENlFpyqB?	M2jtPGROW09?	NVTz[VRTcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>?	M2n6OVI2PDJ4NUS4
NCI-H23	NYPTSlg4TnWwY4Tpc44hSXO\|YYm=	M1L1NFExyqEQvF2=	M1\PZ\|IycMLi	M{jsSmROW09?	MV7k[YNz\WG\|ZYOgeIhmKE[xeF2xJIxmfmWucx?=	MoDkNlU1OjZ3NEi=
A2780	M3v0dGZ2dmO2aX;uJGF{e2G7	MkPTNVDDqM7:TR?=	MYeyNYjDqA>?	NVfnOXp1TE2VTx?=	M4LyboRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz	NGP4eoQzPTR{NkW0PC=>
HCT116	MVvGeY5kfGmxbjDBd5NigQ>?	NUPvc5ptOTBiwsXN	M{HDZlI1KGh?		M2GwR4NifXOnczDhJJA2Oy2mZYDlcoRmdnRidHX0doFxdG:rZDDHNU1ienKnc4SgbY4h\GmybH;p[EBJS1RzMU[gZ4xwdmW\|IFSzJIFv\CCGOB?=	M{PrWVI2OzhyMEW1
MCF-10CA1a	M2XodmZ2dmO2aX;uJGF{e2G7	MU[xNOKh\|ryP	MmTzOFghcA>?	MYLEUXNQ	MonVbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>?	NFPYWIszPTJ3N{eyPS=>
MCF-10A1	M1HocGZ2dmO2aX;uJGF{e2G7	M4HlVFExyqEQvF2=	M335WlI1NzR6IHi=	MWfEUXNQ	MV7pcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG\|dDDldIl1cGWuaXHsxsA>	M2XuSFI2OjV5N{K5
MCF-10CA1a	MonOSpVv[3Srb36gRZN{[Xl?	MWGxNOKh\|ryP	NVLCWJFwOjRiaB?=	NVi5dY0{TE2VTx?=	NX;RemN2\GWlcnXhd4V{KHSqZTDUS2Yu\|rJ\|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh\|rMEoEO=	NUfvcGx2OjV{NUe3Nlk>
MCF-10CA1a	NXjBcI92TnWwY4Tpc44hSXO\|YYm=	MYixNOKh\|ryP	NUDGSXVQOjRiaB?=	M1rpe2ROW09?	NUTEZoZicW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;u	NH70SZkzPTJ3N{eyPS=>
SK-BR-7	M4DqeWZ2dmO2aX;uJGF{e2G7	Mkn6NVDDqM7:TR?=	MX6yOEBp	NEf4VmNFVVOR	MmLFbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	MorCNlUzPTd5Mkm=
SUM102PT	NIHTUGdHfW6ldHnvckBCe3OjeR?=	NH23VZUyOMLizszN	NXzuXYNsOjRiaB?=	Mo\5SG1UVw>?	NGXIb\|JqdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	MX:yOVI2Pzd{OR?=
RAW 264.7	MVPGeY5kfGmxbjDBd5NigQ>?	NIjjOG8yOMLizszN	MVOzNEBucW5?		MVrwdoV3\W62czD0bIUheDV\|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO=	MWeyOVE4OjV2Nx?=
RAW 264.7	MlPhSpVv[3Srb36gRZN{[Xl?	MYixNOKh\|ryP	NYrrbXlpOzBibXnu		NUTw[o5XemWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=>	NELFRm8zPTF5MkW0Oy=>
RAW 264.7	MWLGeY5kfGmxbjDBd5NigQ>?	MmXTNVDDqM7:TR?=	M4TENVMxKG2rbh?=		M2HQfIlvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=>	NHn3d\|EzPTF5MkW0Oy=>
MCF7	NF3ObWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWCyMlUhyrWP	Mm\1OUBl	M1nRZWROW09?	MoDQd4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?=	NHnMbmYzPTB6NUmwNi=>
MCF7	NGTQcWJHfW6ldHnvckBCe3OjeR?=	M4HONlIvPSEEtV2=	MmjaOFghcA>?	NWXUTnRoTE2VTx?=	MYDk[YNz\WG\|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=>	MUOyOVA5PTlyMh?=
ACHN	MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mnf0NE42NTFyIN88US=>	MUOwMVYh\A>?	MX7EUXNQ	NIriUWdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkHzNlUxPjd5OEe=
Caki-2	M2WzfWNmdGxiVnnhZoltcXS7IFHzd4F6	M4\YS\|AvPS1zMDFOwG0>	M4XVc\|AuPiCm	NGmzOJFFVVOR	NHm4NWNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MojFNlUxPjd5OEe=
A498	NYLCbIpNS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkP3NE42NTFyIN88US=>	NXTabWdXOC14IHS=	MWHEUXNQ	MkDMbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NWHW[HlKOjVyNke3PFc>
115	NGfmU4JE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVnMPIlOOC53LUGwJO69VQ>?	MYCwMVYh\A>?	NYixcJoyTE2VTx?=	MnHqbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NHPmbo8zPTB4N{e4Oy=>
117	M1n5VGNmdGxiVnnhZoltcXS7IFHzd4F6	NGPXOGoxNjVvMUCg{txO	NXvBS3N4OC14IHS=	M33VXGROW09?	Ml\QbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2Tu[VI2ODZ5N{i3
ACHN	M2\3OmZ2dmO2aX;uJGF{e2G7	NG\6RlcxNjVxMT:1JO69VQ>?	NIjvWoc1QCCq	NH;uTXZFVVOR	M3f3NIxm[WS\|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz	NXLZWIxDOjVyNke3PFc>
Caki-2	NG\sdnZHfW6ldHnvckBCe3OjeR?=	NIXBXlkxNjVxMT:1JO69VQ>?	NIHDRmk1QCCq	MXXEUXNQ	MUDs[YFleyC2bzDpcoNz\WG\|ZXSg[ZhxemW\|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>?	Mm[0NlUxPjd5OEe=
A498	MmO0SpVv[3Srb36gRZN{[Xl?	MUCwMlUwOS93IN88US=>	M{S3PFQ5KGh?	NXr6dGQ1TE2VTx?=	MmrBcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC\|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF?	M3nEUFI2ODZ5N{i3
115	MYjGeY5kfGmxbjDBd5NigQ>?	NYDGOFc5OC53L{GvOUDPxE1?	NEmxNWs1QCCq	NVXrcox2TE2VTx?=	NILWWoFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV\|IIThdodmfCCpZX7ld\|ohVUSPMjygZY5lKHB{MR?=	MnjvNlUxPjd5OEe=
ACHN	M4HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTCOUDPxE1?	MnfJOFghcA>?	NXe0fWdwTE2VTx?=	M{n2Uolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=>	NVHTdFA1OjVyNke3PFc>
Caki-2	M2PpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MomzOUDPxE1?	M3PnVlQ5KGh?	MUHEUXNQ	MUPpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2wrC=	NGOxenYzPTB4N{e4Oy=>
A498	NXuydFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFW5dFg2KM7:TR?=	MlLBOFghcA>?	MV7EUXNQ	M{\6Solv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=>	NELETnozPTB4N{e4Oy=>
115	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnUOUDPxE1?	NVfFVXJvPDhiaB?=	MVvEUXNQ	NEX0OmpqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA>	MoT0NlUxPjd5OEe=
ACHN	NX:3R2VRTnWwY4Tpc44hSXO\|YYm=	MVG1JO69VQ>?	NXLtdohZPDhiaB?=	MX3EUXNQ	MoPKbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?=	NFjz[3IzPTB4N{e4Oy=>
Caki-2	MUDGeY5kfGmxbjDBd5NigQ>?	MUW1JO69VQ>?	MoXBOFghcA>?	M3q5O2ROW09?	NYq5cpA6cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=>	NF\tdnUzPTB4N{e4Oy=>
A498	M3u1UGZ2dmO2aX;uJGF{e2G7	MUS1JO69VQ>?	M33Md\|Q5KGh?	MXHEUXNQ	NFizco1qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg	Ml3lNlUxPjd5OEe=
115	NX\QN\|JITnWwY4Tpc44hSXO\|YYm=	M1vobVUh\|ryP	NVLISWtCPDhiaB?=	MmLiSG1UVw>?	NFXHUItqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg	M2K3cFI2ODZ5N{i3
MOLM-13	MX3GeY5kfGmxbjDBd5NigQ>?	M2n6[\|bDqM7:TR?=	MXywMVghcA>?	MlrYSG1UVw>?	M2Kx[Ylv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>?	MX2yOFg5PTB6Mh?=
MOLM-13	NIXrN5lHfW6ldHnvckBCe3OjeR?=	M1[5WlbDqM7:TR?=	M3f1NlYhcA>?	M4n2UGROW09?	M1PMRoVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC\|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC=	MnvCNlQ5QDVyOEK=
HepG2	Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY[3NkBp	NWXCTFB{TE2VTx?=	MUfJR\|UxRTN3Lki2JOKyKDJwOTFOwG0>	MU[yOFg5PDhyOR?=
HepG2/As	M2DQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPpO\|IhcA>?	MVvEUXNQ	NYf5PZZUUUN3ME22PE4yOyEEsTC5MlYh\|ryP	Ml\4NlQ5QDR6MEm=
SMMC7721	NVu1[FVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\iT\|czKGh?	M{LjemROW09?	MoS2TWM2OD1\|MT6yPEDDuSB2LkKg{txO	MXyyOFg5PDhyOR?=
SMMC7721/Ac	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUjvVYhUPzJiaB?=	Mn\NSG1UVw>?	M37jXWlEPTB;NUWuNlEhyrFiNT6wN{DPxE1?	MXyyOFg5PDhyOR?=
Huh-7	NWXVUFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmSzO\|IhcA>?	MXvEUXNQ	MmLmTWM2OD1\|Mz65OkDDuSB\|Lkmg{txO	NETleGMzPDh6NEiwPS=>
Hep3B	NVztR4tET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2fjR\|czKGh?	M4nRdWROW09?	M{T3XmlEPTB;MkCuNVghyrFiMT64OEDPxE1?	Mk\tNlQ5QDR6MEm=
HepG2	MoDiRZBweHSxc3nzJGF{e2G7				Ml\YbY5lfWOnczDhdI9xfG:\|aYO=	NIWwN2UzPDh6NEiwPS=>
SMMC7721	NX3FVIo3SXCxcITvd4l{KEG\|c3H5				MWLpcoR2[2W\|IHHwc5B1d3Orcx?=	MlH5NlQ5QDR6MEm=
Huh-7	NFzsdW5CeG:ydH;zbZMhSXO\|YYm=				MoDhbY5lfWOnczDhdI9xfG:\|aYO=	NH3YfmgzPDh6NEiwPS=>
Hep3B	NHS1OWxCeG:ydH;zbZMhSXO\|YYm=				NXXueod3cW6mdXPld{BieG:ydH;zbZM>	MoH2NlQ5QDR6MEm=
U2OS	NVj5VI1KTnWwY4Tpc44hSXO\|YYm=	NX7lbJVHOjBizszN	NHrnXFkzPCCq		MXjpcoNz\WG\|ZYOgeIhmKG2UTlGgcIV3\Wy\|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ	MXWyOFg3PzJ3OR?=
AML2	MnTCRZBweHSxc3nzJGF{e2G7	Ml3ZNk8yOCEQvF2=	NEn1foYzPC92ODDo		MkjJbY5lfWOnczDhdI9xfG:\|aYO=	MnTRNlQ3PTl5NEm=
MOML13	MUTBdI9xfG:\|aYOgRZN{[Xl?	MoTKNk8yOCEQvF2=	NVXMSVNyOjRxNEigbC=>		MXfpcoR2[2W\|IHHwc5B1d3Orcx?=	NV22VHY3OjR4NUm3OFk>
AML2	NWftTYJ3TnWwY4Tpc44hSXO\|YYm=	Ml\lNVDPxE1?	MofGNk81KGh?		MljCbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO=	MVqyOFY2QTd2OR?=
AML3	MW\GeY5kfGmxbjDBd5NigQ>?	NXLLPJhSOTEQvF2=	NIXnUYMzNzRiaB?=		NWjUW3E5cW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>	NES4WJkzPDZ3OUe0PS=>
MOML13	MYnGeY5kfGmxbjDBd5NigQ>?	MlHyNVDPxE1?	M1SzO\|IwPCCq		NXvlTnlIcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>	NEjrUYwzPDZ3OUe0PS=>
BeWo	NV7MUpU{TnWwY4Tpc44hSXO\|YYm=	NHPhbZE{OCEEtV2=	MmTiNlQhcA>?		NV33U3dmcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt	MYmyOFQ6QDF3NB?=
BeWo	MXTBdI9xfG:\|aYOgRZN{[Xl?	NYXVRoJyOzBiwsXN	NEHkZpgzPCCq		M122bYlv[3KnYYPld{BieG:ydH;zbZM>	MVSyOFQ6QDF3NB?=
OCI	MYTGeY5kfGmxbjDBd5NigQ>?	M{LzS\|ExKM7:TR?=	NIXqZ4QzPCCq		MoWzeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w	MVqyOFQ4OzV4Mh?=
MOLM	MoDrSpVv[3Srb36gRZN{[Xl?	NYK3W49bOTBizszN	NVnHR\|ExOjRiaB?=		Mlj4eZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w	NUGxSHMzOjR2N{O1OlI>
U2OS	Mk\RSpVv[3Srb36gRZN{[Xl?	M4rYblIxKM7:TR?=	M4KzfVI1KGh?		NFr3SHhqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw	NVTuU4ozOjR\|Nk[wNFc>
RKO	NXLq[WM{TnWwY4Tpc44hSXO\|YYm=	M4GwbVIxKM7:TR?=	NV34Z3RzOjRiaB?=		NWm2bJlicW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?=	MnH6NlQ{PjZyMEe=
U2OS	MUHGeY5kfGmxbjDBd5NigQ>?	NXvrUVNwOjBizszN	M{\VW\|I1KGh?		NYP0ZWM{cW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44>	MUmyOFM3PjByNx?=
RKO	M4Hnb2Z2dmO2aX;uJGF{e2G7	NFXGUmMzOCEQvF2=	NGrnbWMzPCCq		MVrpcoR2[2W\|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?=	NFnJd2czPDN4NkCwOy=>
SMMC-7721	NEDRWYlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MmCwNU4zPS1{MDFOwG0>	NEH1W\|kzPC92OD:3NkBp	NEDQUJZFVVOR	NIf4XVBqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	M1nmfVI1Ojh4M{Gy
HuH-7	NFzG[otE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MmrTNU4zPS1{MDFOwG0>	NFfSW3QzPC92OD:3NkBp	MXTEUXNQ	MnPDbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	NWfLdmp1OjR{OE[zNVI>
SMMC-7721	NWn3SG1sSXCxcITvd4l{KEG\|c3H5	Mni1NlAh\|ryP	NV7Tb3lFPDhiaB?=	MVnEUXNQ	NXXTUolscW6mdXPld{BieG:ydH;zbZM>	M1fXVVI1Ojh4M{Gy
HuH-7	M1mxSmFxd3C2b4Ppd{BCe3OjeR?=	NF3MeJgzOCEQvF2=	NFjyO\|k1QCCq	NILw[YFFVVOR	M4XWb4lv\HWlZYOgZZBweHSxc3nz	MX[yOFI5PjNzMh?=
SMMC-7721	NYLlbnlQTnWwY4Tpc44hSXO\|YYm=	MVyxNEDPxE1?	NHvQVHk{PiCq	MUTEUXNQ	Monv[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW\|c3nvckBt\X[nbDDv[kBxcG:\|cHjvMXNmejN7Mj3wOVM>	NVvLTploOjR{OE[zNVI>
HuH-7	MnTDSpVv[3Srb36gRZN{[Xl?	NF7jPGMyOCEQvF2=	MVmzOkBp	M3\ifWROW09?	M4PrV4Rwf25vcnXneYxifGW\|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ\|OUKtdFU{	M4TCfVI1Ojh4M{Gy
AT2	MWnGeY5kfGmxbjDBd5NigQ>?	MVG1M\|ExKM7:TR?=			M2DNU4xm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO\|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li	NFX1OIszPDJ2MEKwNy=>
REH	M1TaNGZ2dmO2aX;uJGF{e2G7	Mlz5OU8yOCEQvF2=			MV\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>?	M3;BR\|I1OjRyMkCz
UoCB6	NYXWVndLTnWwY4Tpc44hSXO\|YYm=	NFXvXHk2NzFyIN88US=>			MU\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>?	M3S0VlI1OjRyMkCz
AT2	NEfBOHpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NULmcIVMOC1{NTFOwG0>			M3jzWYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NHvDNmkzPDJ2MEKwNy=>
REH	M2DHU2NmdGxiVnnhZoltcXS7IFHzd4F6	NVHyWZBVOC1{NTFOwG0>			MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NEXvUI8zPDJ2MEKwNy=>
UoCB6	NF\zO5ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXWx[JNQOC1{NTFOwG0>			NE[wclFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NH32PYYzPDJ2MEKwNy=>
A2780	M4P4d2Z2dmO2aX;uJGF{e2G7	NVq1RmdTPS9zMD:yNEDPxE1?	NXLGPFBEOjRiaB?=		MWL1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>?	M1vNW\|I1OTN4MUS3
H460	Ml36SpVv[3Srb36gRZN{[Xl?	MWW1M\|ExNzJyIN88US=>	NHizd\|YzPCCq		MVH1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>?	M2i2T\|I1OTN4MUS3
Lovo	MlewSpVv[3Srb36gRZN{[Xl?	M1;TN\|UwOTBxMkCg{txO	NGH2NpQzPCCq		M4TsZ5VxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi	NGrweXczPDF\|NkG0Oy=>
A2780	MXXBdI9xfG:\|aYOgRZN{[Xl?	MUW1M\|ExNzJyIN88US=>	NXjVNndrOjRiaB?=		NUfNN4tl\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx?	M3TKUVI1OTN4MUS3
H460	MmHkRZBweHSxc3nzJGF{e2G7	M2XqcFUwOTBxMkCg{txO	NITDNmQzPCCq		NXPxNI1b\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx?	M1K2clI1OTN4MUS3
Lovo	MUTBdI9xfG:\|aYOgRZN{[Xl?	NGHVNI02NzFyL{KwJO69VQ>?	MVuyOEBp		NITwZ2RmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>?	NY[3fVhVOjRzM{[xOFc>

... Click to View More Cell Line Experimental Data

体内研究

Nutlin-3 按200 mg/kg 剂量口服处理，每天两次，持续3周，显著抑制SJAS-1移植瘤生长，抑制达90%, 而Doxorubicin抑制81%肿瘤生长。^[1]

激酶实验： ^[1]	+ 展开 Biacore 研究: 在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5，用于固定 PentaHis抗体，为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm²)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO，浓度为10 mM，然后进一步稀释，在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25^oC下进行实验。在Nutlin-3存在时，计算MDM2-p53结合情况，作为结合百分数，使用Microsoft Excel计算IC50。
细胞实验： ^[1]	+ 展开 Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435 Concentrations: 溶于DMSO,终浓度为~ 30 μM Incubation Time: 8, 24, 和 48 小时 Method: 使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法（TUNEL）染色，使用流式细胞仪和荧光显微镜测定细胞凋亡。 (Only for Reference)
动物实验： ^[1]	+ 展开 Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠 Formulation: 在 2% Klucel, 0.5% Tween-80配制中配制 Dosages: 200 mg/kg Administration: 口服处理，每天两次 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	100 mg/mL (171.96 mM)
	Ethanol	30 mg/mL (51.59 mM)
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Nutlin-3 SDF

分子量	581.5
化学式	C₃₀H₃₀Cl₂N₄O₄
CAS号	890090-75-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?
回答：
It is a racemate.

研究领域

产品类型

Nutlin-3

客户购买Selleck的此次产品后发表的文献11篇：

客户使用该产品的5个实验数据：

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Nutlin-3 SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Mdm2 Signaling Pathway Map

相关Mdm2产品